Outcome of the board meeting for submission of un-audited financial results for the quarter ended 30.06.02025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Brawn Biotech's board approved unaudited Q1 FY26 results on 13 August 2025. Revenue from operations jumped to Rs. 579.77 lacs from Rs. 406.41 lacs in Q1 FY25, a YoY growth of about 43%. Total income stood at Rs. 588.86 lacs versus Rs. 406.41 lacs a year ago. The company swung from a loss of Rs. 52.81 lacs in Q1 FY25 to a profit of Rs. 23.60 lacs in Q1 FY26, translating to basic EPS of Rs. 0.89 versus a loss per share of Rs. 1.83 earlier. The statutory auditor, Rajiv Udai & Associates, issued an unqualified (clean) limited review report with no qualifications or emphasis-of-matter paragraphs. For context, FY25 (full year) had closed with a loss of Rs. 179.81 lacs, so this quarter marks a notable turnaround.
A clear sequential and YoY turnaround with strong revenue growth and a return to profitability is a positive signal for shareholders. However, given the company's small scale and prior-year losses, sustainability of this performance in upcoming quarters will be key to watch.